SSRI antidepressants — Competitive Intelligence Brief

SSRI antidepressants (SSRI antidepressants) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective serotonin reuptake inhibitor (SSRI). Area: Psychiatry / Neurology.

marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT) Psychiatry / Neurology Small molecule

Target snapshot

SSRI antidepressants (SSRI antidepressants) — Nanjing Medical University. SSRIs block the reuptake of serotonin at the presynaptic neuron, increasing serotonin availability in the synaptic cleft.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SSRI antidepressants TARGET	SSRI antidepressants	Nanjing Medical University	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Lexapro	escitalopram	Generic (originally Lundbeck/Forest)	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin (5-HT) reuptake transporter	2002-08-14
Prozac	fluoxetine	Eli Lilly and Company	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
citalopram (SSRI)	citalopram (SSRI)	Fundació Sant Joan de Déu	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Sertraline [Zoloft]	Sertraline [Zoloft]	Johns Hopkins University	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
citalopram (celexa)	citalopram (celexa)	Sunnybrook Health Sciences Centre	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Zoloft tablets	Zoloft tablets	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective serotonin reuptake inhibitor (SSRI) class)

1. University of Texas Southwestern Medical Center · 3 drugs in this class
2. Johns Hopkins University · 2 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Daiichi Sankyo Co., Ltd. · 1 drug in this class
5. Guangdong Provincial People's Hospital · 1 drug in this class
6. Janssen Research & Development, LLC · 1 drug in this class
7. Medical University of Vienna · 1 drug in this class
8. Massachusetts General Hospital · 1 drug in this class
9. Fundació Sant Joan de Déu · 1 drug in this class
10. Centre Hospitalier Universitaire Dijon · 1 drug in this class